TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00974701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam ESO2
Description: The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
Study: NCT00517075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Study: NCT02676752

Intervention type: PROCEDURE
Intervention: Medical Examination
Description: Evaluation of secondary lymphedema and fibrosis (LEF) status

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Completion of questionnaires

Intervention type: PROCEDURE
Intervention: Shear Wave Elastography
Description: Undergo ultrasound shear wave elastrography
Study: NCT03456167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoverWell mobile app for follow-up care
Description: The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
Study: NCT00390455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT02117232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visualization balloon
Description: The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CO2 insufflation colonoscopy
Description: Traditional colonoscopy performed with CO2 insufflation without Visualization balloon
Study: NCT03447730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1020
Description: SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1020
Description: SYNB1020 was supplied at a concentration of approximately 1 × 10\^11 CFU/mL in a buffered solution in 5 mL cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo orally in a chilled buffered solution (100 mL).
Study: NCT04696718

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation
Description: the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation
Description: the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily supplementation
Description: the patients will consume 1 pill of probiotic each day for 28 days per treatments each treatment is separated by a wash out period of 21 days
Study: NCT02932969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231 Placebo
Study: NCT00157651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
Study: NCT04346550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suction drain
Description: Post operatively, in both arms including drain group and no drain group, parameters of pain was assessed by visual analog scale (VAS) from 0 (no pain) to 10 (worst pain), assessed at 1st postoperative day by the duty doctor or the nurse. VAS \> 3 was considered as post surgical pain. The total number of hospital stay was noted from the day of operation till the day of discharge and discharge criteria was taken as a patient having pain as per VAS\<3, no fever and tolerating oral intake
Study: NCT05268484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perturbation-based Training with visual cues using Neurocom
Description: Participants will participate in 16 anticipatory postural adjustments (APA) and compensatory postural adjustments (CPA) training sessions using the Neurocom Balance Platform. Each session will last for 1 hour. During the APA portion, a visual cue on the front screen in the form of a countdown timer showing the remaining seconds to the onset of the upcoming perturbation. This information will allow an opportunity for the participant to adjust their posture to handle the upcoming perturbation in the best possible way and also train them to anticipate upcoming disturbances and execute corrective motor outputs. This will ensure the generation of APA in a consistent and repetitive manner. In CPA, after a 5 second pause, the platform will oscillate at 1 Hz, with a constant amplitude, in the anterior-posterior direction for 50 seconds, followed by an additional 5 second quiet period. The participant will wear a safety harness at all times and a spotter will be present at all times.
Study: NCT03438240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Plus 50 µg fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Plus 50 µg dexmedetomidine
Study: NCT00885573

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of pharyngeal sensitivity (SENSITEST)
Description: Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
Study: NCT03869515

Intervention type: OTHER
Intervention: No intervention
Description: It's an observational study, so no intervention will be carried out.
Study: NCT02693834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Leaf spring AFO
Description: Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Leaf spring AFO
Description: Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double adjustable AFO
Description: Double adjustable AFO is a custom AFO with double action metal upright joints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double adjustable AFO
Description: Double adjustable AFO is a custom AFO with double action metal upright joints
Study: NCT05434221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPE
Description: The experimental group receives the COPE during their internships. The COPE consists of two part: (1) communication skills teaching and simulation practice; (2) clinical communication teaching: record the clinical treatment process of the interns and turn them into verbatim drafts. Experts then complied the strengths and weaknesses of the interns' communication skills based on the verbatim manuscripts and gave feedback on the interns' communication skills.~The interns in the experimental group will participate 1 time of the communication skills teaching and simulation practice, and 3 times of the clinical communication teaching in three months.
Study: NCT03438604

Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System

Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System

Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System
Study: NCT01676740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement,
Description: Pills to be swallowed

Intervention type: DRUG
Group type: OTHER
Intervention: Iron Supplement,
Description: Pills to be swallowed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of active drug or placebo
Study: NCT03234517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Clindamycin Cream
Description: Vaginal Clindamycin Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Clindamycin Cream
Description: Vaginal Clindamycin Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Probiotic
Description: Vaginal Probiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Probiotic
Description: Vaginal Probiotic
Study: NCT03806504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
Study: NCT02991144

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAV8OTC
Description: non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAV8OTC
Description: non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAV8OTC
Description: non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAV8OTC
Description: non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactive Corticosteroid Taper Regimen
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactive Corticosteroid Taper Regimen
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactive Corticosteroid Taper Regimen
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to baseline levels.~Corticosteroid treatment will be considered when a participant's alanine aminotransferase (ALT) level exceeded the upper limit of normal (ULN) and the ALT increase was considered by the Investigator to be related to DTX301.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Corticosteroid Taper Regimen
Description: Oral prednisone \[or oral prednisolone\] 60 mg/day at least 5 days prior to DTX301 administration, tapered over 9 weeks.~A prophylactic corticosteroid taper regimen will be administered to prevent or minimize transient vector-induced hepatic effects.
Study: NCT00007475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Description: A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: For GFR \> 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR \< 50 ml/min/1.73 m2 but \> 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
Study: NCT00260819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bosentam TRACLEER
Description: Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
Study: NCT03311022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam Hydrochloride 30mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acupan® 30mg Tablets
Study: NCT03788902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
Study: NCT01155661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684 (edivoxetine)
Description: 12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
Study: NCT06116201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Estradiol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estradiol and Anti-Androgen
Description: Estradiol and Anti-Androgen

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention
Study: NCT05983926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal colectomy was performed
Description: Colonic subtotal resection, also known as subtotal colectomy, is a surgical procedure used to treat colonic diseases such asconstipation, colon cancer, ulcerative colitis, and others.~The purpose of this surgery is to remove a portion of the colon in the patient's body. Unlike a total colectomy, which involves removing the entire colon, a subtotal colectomy only removes a portion of the colon. The procedure typically involves removing the diseased part of the colon and reconnecting the remaining colon. This allows for the preservation of some normal colonic function, enabling the patient to have regular bowel movements.
Study: NCT00562978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AHSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AHSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT04002219

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beverage containing mushroom-extracts
Description: Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beverage containing mushroom-extracts
Description: Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
Study: NCT01458184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PhoneCare system
Description: The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation).
Study: NCT02926235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acid
Description: Treatment arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00994786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
Study: NCT01906021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT/CBCT thermometry method
Description: The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Probe
Description: Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
Study: NCT02833844

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evolocumab
Description: Dose of subcutaneous evolocumab QM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Dose of subcutaneous evolocumab QM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose of matching placebo QM
Study: NCT03562286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.